The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia.
Cancer Program, Biomedical Discovery Institute, Monash University, Melbourne, VIC 3800, Australia; Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia.
Curr Opin Struct Biol. 2024 Dec;89:102932. doi: 10.1016/j.sbi.2024.102932. Epub 2024 Sep 24.
The PEAK family of pseudokinase scaffolds, comprising PEAK1 (originally termed SgK269), PEAK2 (SgK223, the human orthologue of rat Pragmin) and PEAK3 (C19orf35), have emerged as important regulators and integrators of cellular signaling and also play oncogenic roles in a variety of human cancers. These proteins undergo both homo- and heterotypic association that act to diversify signal output. Recently, structural and functional characterization of PEAK3 and its protein-protein interactions have shed light on PEAK signaling dynamics and the interdependency of PEAK family members, how PEAK dimerization regulates the binding of downstream effectors, and how 14-3-3 binding acts to regulate PEAK3 signal output. These important advances form the basis of this review.
PEAK 家族的假激酶支架,包括 PEAK1(最初称为 SgK269)、PEAK2(SgK223,大鼠 Pragmin 的人类同源物)和 PEAK3(C19orf35),已成为细胞信号传导的重要调节剂和整合器,并且在多种人类癌症中发挥致癌作用。这些蛋白质经历同型和异型的缔合,从而使信号输出多样化。最近,PEAK3 的结构和功能表征及其蛋白质-蛋白质相互作用揭示了 PEAK 信号转导动力学以及 PEAK 家族成员的相互依赖性,PEAK 二聚化如何调节下游效应物的结合,以及 14-3-3 结合如何调节 PEAK3 的信号输出。这些重要的进展构成了本综述的基础。